Pascal Rathelot

List of Publications by Year
in descending order

22	688	567281 15	677142 22
papers	citations	h-index	g-index

22	22	22	769
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and antiplasmodial activity of new 4-aryl-2-trichloromethylquinazolines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 396-401.	2.2	134
2	Body image and psychological distress in women with breast cancer: a French online survey on patientsâ€™ perceptions and expectations. Breast Cancer, 2018, 25, 303-308.	2.9	70
3	Synthesis and in vitro antiplasmodial evaluation of 4-anilino-2-trichloromethylquinazolines. Bioorganic and Medicinal Chemistry, 2009, 17, 4313-4322.	3.0	51
4	Discovery of a new antileishmanial hit in 8-nitroquinoline series. European Journal of Medicinal Chemistry, 2012, 54, 75-86.	5.5	50
5	Tandem synthesis and inÂvitro antiplasmodial evaluation of new naphtho[2,1-d]thiazole derivatives. European Journal of Medicinal Chemistry, 2012, 55, 315-324.	5.5	36
6	Highly efficient microwave assisted Î±-trichlorination reaction of Î±-methylated nitrogen containing heterocycles. Tetrahedron, 2006, 62, 8173-8176.	1.9	35
7	Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series. Bioorganic and Medicinal Chemistry, 2013, 21, 7155-7164.	3.0	35
8	Synthesis and inÂvitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents. European Journal of Medicinal Chemistry, 2014, 83, 26-35.	5.5	35
9	4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6003-6006.	2.2	32
10	Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2019, 10, 34-39.	2.8	31
11	Targeting the human malaria parasite Plasmodium falciparum: In vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series. European Journal of Medicinal Chemistry, 2011, 46, 4184-4191.	5.5	27
12	Sonogashira cross-coupling reaction in 4-chloro-2-trichloromethylquinazoline series is possible despite a side dimerization reaction. Tetrahedron, 2013, 69, 2987-2995.	1.9	22
13	Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold. European Journal of Medicinal Chemistry, 2017, 125, 68-86.	5.5	20
14	8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases. European Journal of Medicinal Chemistry, 2018, 157, 115-126.	5.5	19
15	Convenient Preparation of Original Vinylic Chlorides with Antiparasitic Potential in Quinoline Series. Letters in Organic Chemistry, 2006, 3, 891-897.	0.5	18
16	Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series. European Journal of Medicinal Chemistry, 2015, 92, 282-294.	5.5	15
17	8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T.Âb. brucei and cruzi. European Journal of Medicinal Chemistry, 2020, 202, 112558.	5.5	15
18	A New Synthetic Route to Original Sulfonamide Derivatives in 2-Trichloromethylquinazoline Series: A Structure-Activity Relationship Study of Antiplasmodial Activity. Molecules, 2012, 17, 8105-8117.	3.8	12

#	Article	IF	Citations
19	Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series. Bioorganic and Medicinal Chemistry, 2015, 23, 2377-2386.	3.0	12
20	Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T.Âb. brucei hit-compound with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2020, 206, 112668.	5.5	11
21	Development and evaluation of an elective course on the pharmacistâ€™s role in disaster management in France. Journal of Educational Evaluation for Health Professions, 2019, 16, 19.	12.6	6
22	MÃ©dicaments Ã haut risqueÂ: Ã©tat des lieux de leur utilisation dans des services dâ€™hospitalisation conventionnelle adulte au CHU. Pharmacien Hospitalier Et Clinicien, 2018, 53, 223-230.	0.3	2